02 · The exits
02 · The exits
Three paths to liquidity, all already open.
Strategic acquirers, public markets, and late-stage investors are already buying developed-APAC regulatory infrastructure. 5 named outcomes, across 3 of the four markets, from $345M to $2.00B.
Liquidity here is broad, not a single fragile route.
Each named company below reached liquidity through one of three paths. Only one is a strategic acquisition. The opportunity is not "APAC sources, Western acquirers exit." That is one pathway of three, and not the dominant one.
| Path · market | Australia | Japan | New Zealand | Singapore |
|---|---|---|---|---|
| Strategic acquisition | Eucalyptus $240M cash, up to $1.15B total T1 · 2026 | |||
| Public listing | Telix Pharmaceuticals ASX-listed. US$804M revenue, FY2025 T1 · 2017 | Synspective US$76M IPO, ~US$345M valuation T1 · 2024 | ||
| Institutional late-stage | Neara ~US$1.1B valuation, ~US$180M raised T1 · 2026 | Halter ~US$2B valuation, ~US$220M raised T1 · 2026 |
Singapore carries no named outcome yet and stays on the watchlist. Coverage is uneven. More is expected as the 2026 to 2028 compliant cohorts mature.
Near parity at seed. The premium appears later.
Regulated cohort relative to the unregulated cohort. The gap opens by Series C.
2.22x
Observed exit incidence, regulated vs unregulated cohort
13.41% vs 6.03%